Lysosomal Storage Diseases Therapeutics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Treatment (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy, others), By Indication (Gaucher's Disease, Fabry Disease, Pompe's Disease, Mucopolysaccharidosis, others), By End User (Hospitals, Clinics), by region, Competition, Forecast & Opportunities 2018-2028F

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

USD7.60 billion

CAGR (2024-2028)

7.20%

Fastest Growing Segment

Hospitals

Largest Market

North America

 

Market Overview

Global Lysosomal Storage Diseases Therapeutics Market has valued at USD 7.60 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.20% through 2028.  Lysosomal Storage Diseases (LSDs), also known as lysosomal storage disorders, are a group of rare genetic disorders characterized by abnormalities in lysosomes. Lysosomes are cellular organelles responsible for breaking down various molecules and cellular waste products. When lysosomes malfunction due to genetic mutations, they cannot perform their normal functions effectively. As a result, undigested substances accumulate within the lysosomes and disrupt cellular processes. This accumulation leads to a wide range of symptoms and organ damage, affecting multiple systems in the body. Most LSDs result from deficiencies of specific lysosomal enzymes. These enzymes are responsible for breaking down complex molecules, such as lipids (fats), glycoproteins, and mucopolysaccharides. When a particular enzyme is deficient or absent, the corresponding substrate accumulates within lysosomes. There are over 50 different LSDs, each associated with a specific lysosomal enzyme deficiency. Examples of LSDs include Gaucher's disease, Tay-Sachs disease, Fabry disease, Pompe disease, Niemann-Pick disease, and mucopolysaccharidoses (MPS). Each LSD has its unique clinical features and disease course.

Ongoing research into the underlying genetic and molecular mechanisms of LSDs has led to the discovery of new therapeutic targets and treatment approaches. This has resulted in the development of innovative therapies and the expansion of the LSDs therapeutics market. Efforts by patient advocacy groups, healthcare professionals, and educational campaigns have raised awareness about LSDs. Greater awareness leads to earlier diagnosis and treatment initiation, driving the demand for LSD therapies. Regulatory agencies in various countries, such as the U.S. FDA and the European Medicines Agency (EMA), provide orphan drug designation to LSD therapies. This designation offers incentives to pharmaceutical companies, including extended market exclusivity and tax credits, which stimulate investment in LSD drug development. Advances in genetic testing technologies have improved the accuracy and accessibility of LSD diagnoses. This enables early identification of patients and targeted treatment strategies.

Key Market Drivers

Advances in Research and Development

Gene therapy has emerged as a promising approach for treating certain LSDs. Researchers are exploring methods to deliver functional genes into affected cells to restore enzyme production. Clinical trials and studies have shown promising results for diseases like mucopolysaccharidosis type II (Hunter syndrome) and Niemann-Pick disease type A and B. Small molecule chaperones are designed to stabilize mutant enzymes, allowing them to function more effectively. These therapies aim to correct the underlying enzymatic defects in LSDs. Some chaperone therapies have received regulatory approval and are available for patients with conditions like Fabry disease. Substrate Reduction Therapy (SRT) involves reducing the production of the toxic substrate that accumulates in lysosomes in LSDs. Medications like miglustat and eliglustat have been developed as SRTs and are used to treat diseases such as Gaucher's disease and Niemann-Pick type C. Ongoing research has led to the development of improved Enzyme Replacement Therapy (ERTs) with enhanced stability, bioavailability, and pharmacokinetics. These advancements aim to increase the effectiveness and convenience of treatment for patients with LSDs. Researchers are investigating the potential benefits of combining different therapeutic approaches, such as ERTs with chaperone therapies or gene therapy with small molecules. These combinations may offer synergistic effects and improved patient outcomes. Advances in biomarker research have led to the identification of specific markers that can aid in the diagnosis, monitoring, and assessment of disease progression in LSDs.

Biomarkers play a crucial role in clinical trials and personalized treatment strategies. Patient registries and natural history studies have provided valuable insights into the long-term effects of LSDs and the natural course of the diseases. These studies inform clinical trial design and help researchers better understand the needs of patients. Non-invasive diagnostic methods, such as newborn screening and imaging techniques, have improved early detection of LSDs, allowing for timely intervention and treatment initiation. Gene-editing technologies like CRISPR-Cas9 hold promise for correcting disease-causing mutations in LSDs. Research in genome editing techniques continues to advance, opening new possibilities for precision medicine. Collaborative efforts among researchers, clinicians, pharmaceutical companies, and patient advocacy groups at a global level have accelerated R&D in LSD therapeutics. These collaborations facilitate the sharing of knowledge and resources. Advances in molecular biology and genetics have deepened our understanding of the molecular mechanisms underlying LSDs, enabling researchers to develop more targeted therapies. This factor will help in the development of the Global Lysosomal Storage Diseases Therapeutics Market.

Rising Demand Orphan Drug Designation

Orphan Drug Designation provides pharmaceutical companies with various incentives, including extended market exclusivity, tax credits, and reduced regulatory fees. These incentives make the development of LSD therapies more financially attractive for companies. Upon receiving orphan drug status, a drug may be granted several years of market exclusivity, during which competitors are generally prohibited from marketing the same drug for the same orphan indication. This exclusivity ensures that the developer has a period of limited competition in the market, potentially leading to higher pricing and increased demand. The incentives associated with orphan drug status can help offset the high costs of developing therapies for rare diseases like LSDs. This can encourage pharmaceutical companies to invest in research and development for these conditions. LSDs are rare diseases, and the patient populations are small. Orphan Drug Designation acknowledges the challenges of developing treatments for such conditions and provides an opportunity for pharmaceutical companies to serve a niche market.

Orphan drugs often benefit from expedited regulatory review processes, such as fast-track designation and priority review. This accelerates the time to market approval, making these therapies available to patients sooner. Orphan drug status in one country can sometimes lead to similar designations in other countries. This can facilitate the global expansion of LSD therapies, further increasing their demand. The orphan drug market, including LSD therapeutics, has attracted the attention of investors and venture capitalists due to its potential for high returns on investment. This increased investment can drive further demand for research and development. Orphan Drug Designation underscores the importance of addressing unmet medical needs in rare diseases. Patients and advocacy groups often advocate for these designations to encourage pharmaceutical companies to develop treatments for LSDs, improving patient access to therapies. Designation as an orphan drug fosters collaboration between pharmaceutical companies, academic institutions, and research organizations. This collaboration can lead to accelerated research and development efforts in the field of LSD therapeutics. The recognition of LSDs as orphan diseases and the efforts to obtain orphan drug status contribute to greater disease awareness, leading to earlier diagnosis and treatment initiation. This, in turn, drives demand for therapies. This factor will pace up the demand of the Global Lysosomal Storage Diseases Therapeutics Market.

Increasing Genetic Testing and Diagnosis

Genetic testing allows for the early identification of individuals at risk or affected by LSDs. This early diagnosis is essential because many LSDs are progressive, and early intervention can lead to better treatment outcomes. Genetic testing provides a highly accurate and definitive diagnosis of LSDs. It helps differentiate between different types of LSDs, which is essential for selecting the appropriate therapeutic approach. Knowing the specific genetic mutation causing an LSD in an individual allows for personalized treatment strategies. Different mutations may respond differently to therapies, and genetic information guides treatment decisions. In some regions, LSDs are included in newborn screening programs. Newborn screening involves testing for specific genetic markers shortly after birth, enabling the early detection and treatment initiation for affected infants. Genetic testing can identify carriers of LSD mutations, which is valuable for family planning and genetic counseling. It allows individuals to make informed decisions about family planning and assess the risk of passing on the condition to their offspring.

 Genetic testing is often a prerequisite for enrolling patients in clinical trials for LSD therapies. Identifying eligible patients through genetic testing is crucial for conducting research and developing new treatments. Genetic data collected from individuals with LSDs contribute to natural history studies, which provide insights into disease progression and can inform the design of clinical trials and the development of therapeutics. Genetic testing can be used to monitor disease progression and treatment response over time. Changes in genetic markers can provide valuable information about the effectiveness of therapies. Genetic data generated through diagnostic testing contribute to research on the genetic basis of LSDs. This research can lead to the discovery of new therapeutic targets and the development of novel treatments. Genetic testing results offer patients and their family’s clarity and understanding about the disease, its inheritance patterns, and available treatment options. This knowledge can reduce uncertainty and anxiety. Genetic testing results can empower patients and their families to become advocates for themselves and the broader LSD community. Advocacy efforts can raise awareness about LSDs and drive demand for research and therapies. Genetic testing is a cornerstone of precision medicine, where treatments are tailored to individual patients based on their genetic makeup. This approach is increasingly relevant in the field of LSD therapeutics. This factor will accelerate the demand of the Global Lysosomal Storage Diseases Therapeutics Market.


Download Free Sample Report

Key Market Challenges

Limited Understanding of Disease Mechanisms

In many LSDs, the underlying genetic and molecular mechanisms are complex and not fully understood. This complexity makes it challenging to develop targeted therapies that address the root cause of the disease. Without a comprehensive understanding of the disease mechanisms, it is difficult to identify specific drug targets and design effective treatments. LSDs encompass a wide range of rare genetic disorders, each with its unique pathophysiology. Understanding the variations in disease mechanisms among different LSDs is essential for developing tailored treatments. Limited knowledge of these variations can hinder therapeutic development efforts. Biomarkers are crucial for disease diagnosis, monitoring, and assessing treatment efficacy. However, without a deep understanding of disease mechanisms, it can be challenging to identify reliable biomarkers for LSDs, which are necessary for clinical trials and personalized medicine approaches. The lack of insight into disease mechanisms contributes to a high failure rate in drug development for LSDs. Many potential drug candidates do not progress past preclinical or early clinical stages because they do not effectively target the underlying disease processes. In the absence of a clear understanding of disease mechanisms, drug developers may face challenges related to off-target effects. These unintended consequences can lead to safety concerns and hinder the development of safe and effective therapies. The complexity of LSDs and the limited understanding of their mechanisms can make it difficult to secure research funding. Potential investors and grant providers may be hesitant to fund projects without a clear path to success, leading to underfunding of critical research efforts.

Disease Variability

LSDs are a group of rare genetic disorders, and even within the same LSD subtype, there can be significant clinical heterogeneity. Patients with the same genetic mutation may exhibit varying degrees of disease severity and different symptoms. This variability makes it challenging to predict disease progression and tailor treatments to individual patients. The variability in disease presentation can lead to delayed or missed diagnoses. Some patients may not exhibit obvious symptoms early in life, and diagnosis may only occur when symptoms become more pronounced. Delayed diagnosis can result in missed opportunities for early intervention. Individuals with the same LSD subtype and mutation may respond differently to the same therapy. Factors such as age at treatment initiation, disease stage, and individual genetic variations can influence treatment outcomes. Optimizing treatment for each patient can be complex due to this variability. Currently, there are limited tools available to predict the course of the disease in individual patients. Healthcare providers often rely on clinical observation and monitoring, which may not capture subtle changes in disease progression. Variability in disease presentation and progression can pose challenges in designing clinical trials for LSD therapies. Selecting appropriate outcome measures and patient populations that accurately represent the disease can be difficult. The goal of personalized medicine is to tailor treatments to the specific needs of each patient. However, disease variability complicates efforts to develop truly personalized therapies for LSDs. Variability in disease severity means that some patients may require more intensive medical care and support than others. Ensuring that all patients have access to the level of care they need can be challenging.

Key Market Trends

Chaperone Therapies

Chaperone therapies involve the use of small molecules that can stabilize and enhance the activity of misfolded or unstable lysosomal enzymes in LSDs. These molecules act as chaperones by assisting in the correct folding and trafficking of the enzyme to its target location within the lysosome. Chaperone therapies are designed to address the specific genetic mutations that lead to enzyme misfolding and dysfunction in LSDs. They target the underlying cause of the disease by helping the enzyme reach its active form, which is essential for substrate degradation. Many chaperone therapies are administered orally, which is a more convenient and patient-friendly route of administration compared to intravenous infusions or other invasive methods. This can improve treatment adherence and patient quality of life. Chaperone therapies have been developed and tested for various LSDs, including Fabry disease, Pompe disease, Gaucher's disease, and others. This broad applicability makes them relevant to multiple LSD subtypes. Some chaperone therapies have demonstrated clinical success and received regulatory approvals in different regions. For example, migalastat has been approved for the treatment of Fabry disease. Chaperone therapies hold the potential to modify the course of the disease by restoring enzyme activity and reducing substrate accumulation. This can lead to improvements in clinical outcomes and the prevention of disease progression. Researchers are exploring the possibility of combining chaperone therapies with other treatment approaches, such as enzyme replacement therapy (ERT) or gene therapy. These combination therapies may offer synergistic benefits and enhanced treatment efficacy. Chaperone therapies align with the trend toward personalized and precision medicine, where treatments are tailored to individual patients based on their specific genetic mutations and disease manifestations.

Segmental Insights

Treatment Insights

In 2022, the Global Lysosomal Storage Diseases Therapeutics Market largest share was held by enzyme replacement therapy segment and is predicted to continue expanding over the coming years. Enzyme replacement therapy has proven to be an effective treatment for many LSDs, particularly those characterized by a deficiency of a specific lysosomal enzyme. ERTs work by providing the missing or deficient enzyme, which helps to break down the accumulated substances within lysosomes and alleviate symptoms. Several ERTs for various LSDs had received regulatory approval in different regions, including the United States and Europe. These approved therapies included imiglucerase and velaglucerase alfa for Gaucher's disease, alglucerase for Gaucher's disease, laronidase for mucopolysaccharidosis type I, and idursulfase for mucopolysaccharidosis type II, among others. Pharmaceutical companies specializing in rare disease therapeutics often focused on developing and marketing ERTs due to their proven efficacy and the ability to command high prices. These companies invested heavily in research and development to improve existing ERTs and develop new ones.

Indication Insights

In 2022, the Global Lysosomal Storage Diseases Therapeutics Market largest share was held by Gaucher’s disease segment and is predicted to continue expanding over the coming years.  Gaucher's disease is one of the more common LSDs, particularly among Ashkenazi Jewish populations. Its relatively higher incidence compared to other LSDs means there is a larger patient population in need of treatment, contributing to its market prominence. Gaucher's disease was one of the first LSDs for which effective enzyme replacement therapy (ERT) became available. ERTs such as imiglucerase, velaglucerase alfa, and taliglucerase alfa have been developed and widely used to manage Gaucher's disease. Major pharmaceutical companies invested in the development and commercialization of ERTs for Gaucher's disease. These companies recognized the therapeutic need and market potential, which led to substantial resources being dedicated to the development and marketing of Gaucher's disease therapies. Many of the therapies for Gaucher's disease received orphan drug designation and incentives from regulatory agencies, such as the U.S. Food and Drug Administration (FDA). These designations encourage pharmaceutical companies to invest in rare disease treatments.

End-User Insights

In 2022, the Global Lysosomal Storage Diseases Therapeutics Market largest share was held by Hospitals segment in the forecast period and is predicted to continue expanding over the coming years.  Many LSD therapies, including enzyme replacement therapies (ERTs), are administered intravenously or via infusion. Hospitals and specialized treatment centres provide the infrastructure and expertise required for these treatments. Patients often receive their LSD therapies at hospitals or clinics under the supervision of healthcare professionals. Hospitals are typically where patients with LSDs are diagnosed and initially assessed. Additionally, ongoing monitoring of patients' health, disease progression, and treatment response often takes place at hospitals or associated outpatient clinics. Hospitals and academic medical centres are frequently involved in conducting clinical trials for LSD therapies. These trials are essential for testing the safety and efficacy of new treatments before they are approved for broader use.


Download Free Sample Report

Regional Insights

The North America region dominates the Global Lysosomal Storage Diseases Therapeutics Market in 2022. North America, particularly the United States and Canada, has a highly developed and advanced healthcare infrastructure. This includes well-established research institutions, hospitals, and pharmaceutical companies specializing in rare disease therapeutics. These resources are essential for both research and the development of treatments for LSDs. North America has a strong tradition of research and innovation in the field of life sciences and biotechnology. This environment fosters the discovery and development of new therapies, including those for rare diseases like LSDs. The United States has regulatory agencies like the Food and Drug Administration (FDA) that provide incentives and support for the development of orphan drugs, which includes treatments for rare diseases. Orphan drug designations and fast-track approvals have facilitated the introduction of LSD therapies. Many leading pharmaceutical and biotechnology companies with a focus on rare disease therapies are headquartered or have a significant presence in North America. These companies invest in LSD research and development.

Recent Developments

  • In March 2021, The therapy of mucopolysaccharidosis type II (MPS II, or Hunter syndrome), IZCARGO® (pabinafusp alfa 10 mL, intravenous drip infusion), has been approved by the Ministry of Health, Labour and Welfare (MHLW) in Japan, according to a press release from JCR Pharmaceuticals Co., Ltd. Recombinant iduronate-2-sulfatase enzyme replacement therapy (ERT) IZCARGO® (formerly JR-141) uses J-Brain Cargo®, a JCR-developed unique technology, to carry treatments across the blood-brain barrier (BBB). It is the first authorised ERT to ever breach the blood-brain barrier (BBB) by intravenous injection, an advantage that might significantly improve the quality of life for people with LSDs like MPS II. Pabinafusp alfa is a recombinant fusion protein made from an antibody against the human transferrin receptor and idursulfase, an enzyme that is absent or inactive in people with Hunter syndrome (10 mL, intravenous drip infusion). Using transferrin receptor-mediated transcytosis, J-Brain Cargo®, a JCR-exclusive BBB-penetrating technology, it penetrates the BBB, and its absorption into cells is mediated by the mannose-6-phosphate receptor. Pabinafusp alfa is anticipated to be effective against the CNS symptoms of Hunter syndrome according to this new method of action.
  • In December 2022, patients with Gaucher disease who received a single dose of the investigational hematopoietic stem cell (HSC) gene therapy AVR-RD-02 showed stabilisation or reversal of multiple clinically relevant measures, according to new interim pharmacokinetic, pharmacodynamic, and clinical efficacy data released by AVROBIO, Inc., a leading clinical-stage gene therapy company. Additionally, AVROBIO intends to start a worldwide, registrational Phase 2/3 clinical study for Gaucher disease type 3 (GD3) in the second half of 2023 following fruitful conversations with regulators. The most significant and prevalent lysosomal condition is Gaucher disease. People with Gaucher disease type 1 (GD1) often have a shorter life expectancy and may endure incapacitating symptoms that greatly lower their quality of life, even when receiving enzyme replacement therapy (ERT), the current gold standard of care. GD3 is a more severe, progressive type of Gaucher disease that manifests as neurological signs and symptoms as well as more extensive systemic manifestations that are frequently resistant to routine medical treatments.

Key Market Players

  • Pfizer, Inc.
  • Sanofi SA
  • BioMarin Pharmaceutical Inc
  • Actelion Ltd.
  • Raptor Pharmaceutical Corp.
  • Protalix Biotherapeutics Inc.
  • Amicus Therapeutics, Inc.

By Treatment

By Indication

By End-User

By Region
  • Enzyme Replacement Therapy
  • Stem Cell Therapy
  • Substrate Reduction Therapy
  • Others
  • Gaucher's Disease
  • Fabry Disease
  • Pompe's Syndrome
  • Mucopolysaccharidosis
  • Others
  • Hospitals
  • Clinics
  • North America
  • Asia-Pacific
  • Europe
  • South America
  • Middle East & Africa

 

Report Scope:

In this report, the Global Lysosomal Storage Diseases Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  •     Lysosomal Storage Diseases Therapeutics Market, By Treatment:

o   Enzyme Replacement Therapy

o   Stem Cell Therapy

o   Substrate Reduction Therapy

o   Others

  •   Lysosomal Storage Diseases Therapeutics Market, By Indication:

o   Gaucher's Disease

o   Fabry Disease

o   Pompe's Syndrome

o   Mucopolysaccharidosis

o   Others

  •     Lysosomal Storage Diseases Therapeutics Market, By End-User:

o   Hospitals

o   Clinics

  • Global Lysosomal Storage Diseases Therapeutics Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

 

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lysosomal Storage Diseases Therapeutics Market.

Available Customizations:

Global Lysosomal Storage Diseases Therapeutics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Lysosomal Storage Diseases Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.  Markets Covered

1.2.2.  Years Considered for Study

1.2.3.  Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Lysosomal Storage Diseases Therapeutics Market Outlook

5.1.  Market Size & Forecast

5.1.1.        By Value

5.2.  Market Share & Forecast

5.2.1.        By Treatment (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy, others)

5.2.2.        By Indication (Gaucher's Disease, Fabry Disease, Pompe's Disease, Mucopolysaccharidosis, others)

5.2.3.        By End User (Hospitals, Clinics),

5.2.4.        By Company (2022)

5.3.  Market Map

6.    Asia Pacific Lysosomal Storage Diseases Therapeutics Market Outlook

6.1.  Market Size & Forecast

6.1.1.        By Value

6.2.  Market Share & Forecast

6.2.1.        By Treatment

6.2.2.        By Indication

6.2.3.        By End User

6.2.4.        By Country

6.3.  Asia Pacific: Country Analysis

6.3.1.        China Lysosomal Storage Diseases Therapeutics Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.           By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.           By Treatment

6.3.1.2.2.           By Indication

6.3.1.2.3.           By End User

6.3.2.        India Lysosomal Storage Diseases Therapeutics Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.           By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.           By Treatment

6.3.2.2.2.           By Indication

6.3.2.2.3.           By End User

6.3.3.        Australia Lysosomal Storage Diseases Therapeutics Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.           By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.           By Treatment

6.3.3.2.2.           By Indication

6.3.3.2.3.           By End User

6.3.4.        Japan Lysosomal Storage Diseases Therapeutics Market Outlook

6.3.4.1.        Market Size & Forecast

6.3.4.1.1.           By Value

6.3.4.2.        Market Share & Forecast

6.3.4.2.1.           By Treatment

6.3.4.2.2.           By Indication

6.3.4.2.3.           By End User

6.3.5.        South Korea Lysosomal Storage Diseases Therapeutics Market Outlook

6.3.5.1.        Market Size & Forecast

6.3.5.1.1.           By Value

6.3.5.2.        Market Share & Forecast

6.3.5.2.1.           By Treatment

6.3.5.2.2.           By Indication

6.3.5.2.3.           By End User

7.    Europe Lysosomal Storage Diseases Therapeutics Market Outlook

7.1.  Market Size & Forecast

7.1.1.        By Value

7.2.  Market Share & Forecast

7.2.1.        By Treatment

7.2.2.        By Indication

7.2.3.        By End User

7.2.4.        By Country

7.3.  Europe: Country Analysis

7.3.1.        France Lysosomal Storage Diseases Therapeutics Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Treatment

7.3.1.2.2.           By Indication

7.3.1.2.3.           By End User

7.3.2.        Germany Lysosomal Storage Diseases Therapeutics Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Treatment

7.3.2.2.2.           By Indication

7.3.2.2.3.           By End User

7.3.3.        Spain Lysosomal Storage Diseases Therapeutics Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.           By Treatment

7.3.3.2.2.           By Indication

7.3.3.2.3.           By End User

7.3.4.        Italy Lysosomal Storage Diseases Therapeutics Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.           By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.           By Treatment

7.3.4.2.2.           By Indication

7.3.4.2.3.           By End User

7.3.5.        United Kingdom Lysosomal Storage Diseases Therapeutics Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.           By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.           By Treatment

7.3.5.2.2.           By Indication

7.3.5.2.3.           By End User

8.    North America Lysosomal Storage Diseases Therapeutics Market Outlook

8.1.  Market Size & Forecast

8.1.1.        By Value

8.2.  Market Share & Forecast

8.2.1.        By Treatment

8.2.2.        By Indication

8.2.3.        By End User

8.2.4.        By Country

8.3.  North America: Country Analysis

8.3.1.        United States Lysosomal Storage Diseases Therapeutics Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Treatment

8.3.1.2.2.           By Indication

8.3.1.2.3.           By End User

8.3.2.        Mexico Lysosomal Storage Diseases Therapeutics Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Treatment

8.3.2.2.2.           By Indication

8.3.2.2.3.           By End User

8.3.3.        Canada Lysosomal Storage Diseases Therapeutics Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Treatment

8.3.3.2.2.           By Indication

8.3.3.2.3.           By End User

9.    South America Lysosomal Storage Diseases Therapeutics Market Outlook

9.1.  Market Size & Forecast

9.1.1.        By Value

9.2.  Market Share & Forecast

9.2.1.        By Treatment

9.2.2.        By Indication

9.2.3.        By End User

9.2.4.        By Country

9.3.  South America: Country Analysis

9.3.1.        Brazil Lysosomal Storage Diseases Therapeutics Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.           By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.           By Treatment

9.3.1.2.2.           By Indication

9.3.1.2.3.           By End User

9.3.2.        Argentina Lysosomal Storage Diseases Therapeutics Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.           By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.           By Treatment

9.3.2.2.2.           By Indication

9.3.2.2.3.           By End User

9.3.3.        Colombia Lysosomal Storage Diseases Therapeutics Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.           By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.           By Treatment

9.3.3.2.2.           By Indication

9.3.3.2.3.           By End User

10. Middle East and Africa Lysosomal Storage Diseases Therapeutics Market Outlook

10.1.             Market Size & Forecast

10.1.1.     By Value

10.2.             Market Share & Forecast

10.2.1.     By Treatment

10.2.2.     By Indication

10.2.3.     By End User

10.2.4.     By Country

10.3.             MEA: Country Analysis

10.3.1.     South Africa Lysosomal Storage Diseases Therapeutics Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Treatment

10.3.1.2.2.         By Indication

10.3.1.2.3.         By End User

10.3.2.     Saudi Arabia Lysosomal Storage Diseases Therapeutics Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Treatment

10.3.2.2.2.         By Indication

10.3.2.2.3.         By End User

10.3.3.     UAE Lysosomal Storage Diseases Therapeutics Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Treatment

10.3.3.2.2.         By Indication

10.3.3.2.3.         By End User

11. Market Dynamics

11.1.             Drivers

11.2.             Challenges

12. Market Trends & Developments

12.1.             Recent Developments

12.2.             Product Launches

12.3.             Mergers & Acquisitions

13. Global Lysosomal Storage Diseases Therapeutics Market: SWOT Analysis

14. Porter’s Five Forces Analysis

14.1.             Competition in the Industry

14.2.             Potential of New Entrants

14.3.             Power of Suppliers

14.4.             Power of Customers

14.5.             Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

16.1.   Pfizer, Inc.

16.1.1.     Business Overview

16.1.2.     Company Snapshot

16.1.3.     Products & Services

16.1.4.     Financials (In case of listed companies)

16.1.5.     Recent Developments

16.1.6.     SWOT Analysis

16.2.   Sanofi SA

16.2.1.     Business Overview

16.2.2.     Company Snapshot

16.2.3.     Products & Services

16.2.4.     Financials (In case of listed companies)

16.2.5.     Recent Developments

16.2.6.     SWOT Analysis

16.3.   BioMarin Pharmaceutical Inc

16.3.1.     Business Overview

16.3.2.     Company Snapshot

16.3.3.     Products & Services

16.3.4.     Financials (In case of listed companies)

16.3.5.     Recent Developments

16.3.6.     SWOT Analysis

16.4.   Actelion Ltd.

16.4.1.     Business Overview

16.4.2.     Company Snapshot

16.4.3.     Products & Services

16.4.4.     Financials (In case of listed companies)

16.4.5.     Recent Developments

16.4.6.     SWOT Analysis

16.5.   Portea Medical Raptor Pharmaceutical Corp.

16.5.1.     Business Overview

16.5.2.     Company Snapshot

16.5.3.     Products & Services

16.5.4.     Financials (In case of listed companies)

16.5.5.     Recent Developments

16.5.6.     SWOT Analysis

16.6.   Protalix Biotherapeutics Inc.

16.6.1.     Business Overview

16.6.2.     Company Snapshot

16.6.3.     Products & Services

16.6.4.     Financials (In case of listed companies)

16.6.5.     Recent Developments

16.6.6.     SWOT Analysis

16.7.   Amicus Therapeutics, Inc.

16.7.1.     Business Overview

16.7.2.     Company Snapshot

16.7.3.     Products & Services

16.7.4.     Financials (In case of listed companies)

16.7.5.     Recent Developments

16.7.6.     SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Lysosomal Storage Diseases Therapeutics Market was estimated to be USD 7.60 billion in 2022.

down-arrow

Pfizer, Inc., Sanofi SA are some of the key players operating in the Lysosomal Storage Diseases Therapeutics Market.

down-arrow

Lysosomal storage diseases are a group of rare and complex genetic disorders. Understanding the underlying molecular mechanisms for all LSDs can be challenging.

down-arrow

Gene therapy approaches gained momentum in the treatment of LSDs

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Lysosomal Storage Diseases Therapeutics Market to grow with a CAGR of 7.20%

Oct, 2023

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Lysosomal Storage Diseases Therapeutics Market.

Why Choose Us